[ Indi Molecular raises $11.5M in Series A funding ]

Indi Molecular has raised $11.5 million in Series A funding.

Founded in 2013, Indi Molecular  is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents ( PCC).

The Series-A proceeds will be used to establish a high throughput PCC discovery platform and to advance existing leads in PET immuno-oncology imaging to clinical stage.

Funding  Series A
Founded  2013
Country  USA
City  Culver City, California
Founder / CEO  Albert A. Luderer
Deal Size  $11.5M
Investors  Legend Capital
Asset Management Ventures (AMV)
 Merck Ventures
Previous Investors  Asset Management Ventures (AMV)